Perrmission for 46 containers on 'grass and scrubland' thrown out
Plans for 46 containers to be placed on land have been thrown out by planning chiefs.
The proposal was for them to be installed on "vacant grass and scrubland" to the east of the junction of Stoneclough Road and Bolton Road in Kearsley.
The plans, which were submitted on the behalf of applicant John Bowling, also would have seen a single storey outbuilding and "associated works" built on the site.
In his report, planning officer John Dupre recommended for the application to be refused.
In regards to impact on the character and appearance of the site and the surrounding area, he said: "The proposed development will change the character of the site from what is currently an area of undeveloped urban greenspace into one of ad hoc light industrial estate.
"While it is acknowledged that there are other industrial units nearby, these are permanent structures which are more different in terms of form and appearance.
"It is not considered that the development will respect or acknowledge the character and identity of the locality in term of design and siting, nor will it conserve or enhance the distinctive character of the existing physical and natural environment.
Plans (Image: Bolton Council) "The development will not be visually stimulating, nor will it raise the human spirit."
He added that it would have an "undue impact" on the surrounding area.
Mr Dupre added: "No details of have been submitted to show how the existing urban green space will be protected and enhanced in balance with other considerations."
Read more: Developer steps in with upgrades to make cricket fixtures 'about more than sport'
Read more: 14 weeks of roadworks set to start on roundabout notorious for congestion
Read more: Concerns over development access amid 'political atmosphere'
Regarding the impact on the highway, he said that "insufficient information" had been given, with no transport report having been filed.
Referring to the impact on biodiversity and ecology, Mr Dupre added that no details had been given to "show how existing urban green space will be protected and enhanced".
The land is off Stoneclough Road (Image: Google Maps) No risk assessment for contaminated land was submitted, though no objection has been received from the council's Pollution Control team in relation to that aspect.
Mr Dupre added: "The application site appears to include an abandoned mine entry.
"No assessment of risk from this feature has been submitted with the application; however, as the ground works required for their siting is minimal, storage containers are among the types of development that are considered exempt from the need to undertake a Coal Mining Risk Assessment."
Concluding, he said: "For the reasons outlined above, it is not considered that the proposal accords with Bolton's Development Plan policies on design, siting and appearance and that insufficient information has been provided to assess the impact of the development against policies relating to ecology, urban green space and highways and transport.
"It is therefore considered that that planning permission should be refused."
In the council's final decision, it refused the application.
The notice stated: "The proposed development would, by virtue of its design, siting and appearance, be detrimental to the character and appearance of the site and the surrounding area contrary to Policy OA6 of Bolton's Core Strategy, Policy JP-P1 of Places for Everyone Joint Development Plan and Supplementary Planning Document General Design Principles.
"Insufficient information has been provided by the applicant with regard to the impacts of the development in terms of highway safety and transport, ecology and biodiversity net gain and urban green space, to enable the proposal to be properly judged against the policies JP-G6, JP-G8 and JP-C8 of the Places for Everyone Joint Development Plan."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
Yahoo
20 hours ago
- Yahoo
PVH Corp (PVH) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
Revenue Growth: Up 2% on both a reported and constant currency basis. Operating Margin: 8.1% within guidance range. Earnings Per Share (EPS): $2.30, slightly ahead of guidance. Gross Margin: 58.6%, a decrease of 280 basis points compared to last year. Inventory Increase: Up 19% compared to Q1 last year. Direct-to-Consumer Revenue: Down 3% both reported and in constant currency. Wholesale Revenue: Up 7% on a constant currency basis, 6% on a reported basis. EMEA Revenue: Up 4% in constant currency. Americas Revenue: Up 7%, driven by high-teens growth in wholesale. Asia Pacific Revenue: Down 11% on a constant currency basis. Licensing Revenue: Down 2% versus last year. SG&A as a Percent of Revenue: 50.5%, a 90 basis point improvement versus last year. Shareholder Returns: Over $550 million returned through share repurchases. Warning! GuruFocus has detected 7 Warning Signs with CIEN. Release Date: June 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. PVH Corp (NYSE:PVH) reported a 2% revenue growth, exceeding their guidance, driven by disciplined execution of the PVH+ Plan. The company delivered stronger than expected non-GAAP EPS, also above their guidance. Calvin Klein's innovative product franchise, Icon Cotton Stretch underwear, drove a 25% increase in sales globally. Tommy Hilfiger's strategic product innovations and seasonal collections have led to stronger performance, particularly in Europe. PVH Corp (NYSE:PVH) returned over $550 million to shareholders through share repurchases during the quarter. The company is facing a challenging macroeconomic environment, with decreased consumer sentiment and traffic trends, particularly in North America and China. PVH Corp (NYSE:PVH) experienced operational challenges with Calvin Klein's global product creation, impacting margins. The company is dealing with a more promotional environment, leading to increased discounting and impacting gross margins. Tariffs are expected to have a $65 million unmitigated impact on EBIT for the full year. Inventory levels increased by 19% due to lower than expected demand for basics and essentials. Q: Stefan, you mentioned decreased traffic and increased promotional levels. What gives you confidence that Calvin Klein and Tommy Hilfiger still have good momentum with consumers? A: Stefan Larsson, CEO: Despite the challenging macro environment, where we lean into consumer love for Calvin Klein and Tommy Hilfiger, we see strong results. For example, our new product innovation in Calvin Klein men's underwear drove 25% growth in a major franchise. Similarly, fashion denim grew by 14%. We plan to expand these successful strategies across more of our business. Q: Can you provide an update on the cost-out efforts and whether they are affecting operational stability, particularly for Calvin Klein? A: Stefan Larsson, CEO: The operational challenges at Calvin Klein were due to the integration of global product capabilities, which is crucial for future growth. We are seeing improvements, with significant progress expected by Spring 2026. Zachary Coughlin, CFO, added that cost-saving measures are on track, with 200 basis points of SG&A leverage expected by Q4 2025. Q: How are you addressing the impact of tariffs, and what are your strategies for mitigating these effects? A: Zachary Coughlin, CFO: We have identified $65 million in unmitigated tariff effects. Our mitigation strategies include optimizing sourcing and production costs, strategic discount reductions, and targeted pricing actions where we have pricing power. Our globally diversified revenue base and strong supply chain relationships are key advantages. Q: With the expected promotional environment, how do you plan to make the brand more resilient from a pricing perspective? A: Stefan Larsson, CEO: We are focusing on scaling the impact of PVH+ execution by enhancing product innovation in key categories and increasing marketing investments to drive traffic. For example, Tommy Hilfiger's partnership with Formula One is a strategic move to connect the brand with a growing sport and enhance its lifestyle appeal. Q: Can you elaborate on the gross margin outlook for the second quarter and the back half of the year? A: Zachary Coughlin, CFO: For the full year, gross margins are expected to decrease by approximately 250 basis points, with 50 basis points due to tariffs and 100 basis points from increased promotional activity. We anticipate sequential improvement in Calvin Klein's operational issues and expect to mitigate the tariff impact over time. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio